The 2026 Digital Learning Journey in Growth Disorders:
Digital Health and Technologies for Better Patient Outcomes

Thursday **30 April 2026**
From 13:30 to 14:30 CEST

SCIENTIFIC SEMINARS
INTERNATIONAL FOUNDATION

LIVE WEBINAR

The importance of a correct diagnosis: Who, how and when to test for GHD

For registration
CLICK HERE

REGISTRATION IS FREE OF CHARGE

OVERVIEW

The diagnosis of Growth Hormone Deficiency (GHD) can be challenging. Clinical, laboratory, and neuroradiological findings must be interpreted correctly in different periods of life (newborn, childhood, adolescence and transition). A correct diagnosis is crucial for timely intervention and appropriate follow-up

LEARNING OBJECTIVES

- Increase the number of correct diagnoses
- Suspect and diagnose GHD in the neonatal period
- Identify patients with permanent GHD who need to continue Growth Hormone (GH) therapy

TARGET AUDIENCE

Paediatricians, Endocrinologists, Paediatric Endocrinologists

LANGUAGE

English with simultaneous translation into Korean and Spanish

CONTINUING MEDICAL EDUCATION

An application has been made to the EACCME® for CME accreditation of the Case-Based Live Webinar **"The importance of a correct diagnosis: Who, how and when to test for GHD"** to be held on 30th April 2026.

CME PROVIDER

Scientific Seminars International Foundation
Senior Programme Manager: Annamaria Nesticò
annamaria.nestico@scientificseminars.com
education@scientificseminars.com

MEDICAL ADVISOR

Sandro Loche
Bambino Gesù Children Hospital, IRCCS
Rome, Italy

FACULTY

Gerhard Binder
Pediatric Endocrinology
University Children's Hospital
Tübingen, Germany

Sandro Loche
Bambino Gesù Children Hospital, IRCCS
Rome, Italy

Mohamad Maghnie
IRCCS “Giannina Gaslini”
Paediatrics and Paediatric Endocrinology
University of Genoa
Genoa, Italy

SCIENTIFIC PROGRAMME

THE IMPORTANCE OF A CORRECT DIAGNOSIS: WHO, HOW AND WHEN TO TEST FOR GHD

THURSDAY, 30 APRIL 2026
From 13:30 to 14:30 CEST

Chair:		S. Loche (Italy)
13.30		**Welcome and introduction** S. Loche (Italy)
13.35		**L1 Neonatal GHD** G. Binder (Germany)
13.50		**L2 Diagnosis of isolated and idiopathic GHD** S. Loche (Italy)
14.05		**L3 GHD in the transition age** M. Maghnie (Italy)
14.20		**Q&A, General Interactive Discussion with participants** Moderator: S. Loche (Italy)
14.30		**Closing remarks and end of the live webinar** S. Loche (Italy)

LEGEND

 Lecture  Q&A General discussion with participants  Concluding remarks

FACULTY DISCLOSURES

Scientific Seminars International Foundation adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME®) and all other professional organizations, as applicable, which state that programs awarding continuing education credits must be balanced, independent, objective and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices and other products (other than those uses indicated in approved product labelling/package insert for the product) may be presented in the program (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter).
We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so that participants may form their own judgements, based on full disclosure of the facts. Further, all opinions and recommendations presented during the program and all program-related materials neither imply an endorsement nor a recommendation on the part of Scientific Seminars International Foundation. All presentations represent solely the independent views of the presenters/authors.

The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non-EMEA/FDA approved (off-label) uses of drugs:

Gerhard Binder	Declared receipt of honoraria or consultation fees from Merck, Lilly, Novo Nordisk, Pfizer, Ascendis, Ferring, Ipsen, Sandoz
Sandro Loche	Declared receipt of honoraria or consultation fees from Merck and Sandoz
Mohamad Maghnie	Declared receipt of grants/research supports from Merck, Sandoz, Rhythm, BioMarin, Novo Nordisk and receipt of honoraria or consultation fees from Merck, Sandoz, Novo Nordisk , Biomarin, Rhythm, Ascendis

FACULTY
BIOGRAPHIES

SANDRO LOCHE

Sandro Loche is former Head of the Pediatric Endocrinology Unit at the Pediatric Hospital Microcitemico in Cagliari (Italy). He received his medical degree at the University of Cagliari in 1979, training in Pediatrics and Endocrinology at the University of Cagliari and in Pediatric Endocrinology at the Cornell University Medical College, New York. His main areas of scientific interest include growth and growth disorders, neuroendocrine regulation of GH secretion, diagnosis and treatment of GH deficiency, childhood obesity. He has published over 200 articles, reviews and books. He has served as Editor of the Journal of Endocrinological Investigation and is currently associate editor of Frontiers in Endocrinology.
He received the 2015 Cacciari Prize of the Italian Society for Pediatric Endocrinology and Diabetes (SIEDP/ISPED) for excellence in Pediatric Endocrinology. Sandro Loche is a member of many national and international pediatric and endocrine societies including the American Endocrine Society and the European Society for Pediatric Endocrinology and has served in many societies' committees over the years. He has been an invited speaker to numerous national and international meetings. He is currently a senior researcher at the Bambino Gesù Children Hospital. IRCCS, Rome, Italy.

GERHARD BINDER

Gerhard Binder is associate professor and head of the Pediatric Endocrinology section in Tübingen (Germany) since 2008. He was trained by Michael Ranke (Tübingen) and John Parks (Atlanta/Georgia). His major interests are growth hormone deficiency, GH treatment, syndromic short stature, panhypopituitarism and disorders of puberty. He described GH1 splice site mutations causing dominantly transmitted isolated GHD, proposed GH treatment for short children with SHOX deficiency, established the measurement of GH content in newborn screening cards for early diagnosis of severe inborn GHD and discovered genomic IGF2 mutations and described the phenotype. He has published 195 peer-reviewed original papers. He is head of the German Working Group on Growth within the German Society for Pediatric Endocrinology and Diabetology.
Gerhard Binder created and sponsored an RCT with the drug DHEA in 2007 (J Clin Endocrinol Metab 2009; 94:1182). He was principal investigator for two long-acting GH trials in the near past.

MOHAMAD MAGHNIE

Professor Maghnie is a professor of Pediatrics and PhD In Pediatric Endocrinology, Head of the Pediatric Clinic, Clinical Service in Pediatric Endocrinology, Diabetes and Metabolism at the Giannina Gaslini Institute, and Director of the Department of Neuroscience, Rehabilitation, Ophtalmology, Genetics, Maternal and Child Health - DINOGMI, University of Genoa, Italy. He is currently a Director of the Pediatric Residency Program at the University of Genoa, Italy, and the supervisor of several postgraduate research students and postdoctoral fellows working in his research group. Professor Maghnie is a former President of the Italian Society for Pediatric Endocrinology and Diabetology (ISPED, 2011-2015), former Chair of the European Society for Pediatric Endocrinology (ESPE) SPE website (2004–2008), a co-author of Yearbook of Pediatric Endocrinology (2004–2009), and former member of the ESPE Summer School Steering Committee (2010–2013). Professor Maghnie is currently the President of the European Achondroplasia/EAF (Now International Achondroplasia Forum/IAF) Forum and the Coordinator of the Corporate Liaison Board of the ESPE 2023-2026. Professor Maghnie received national and international award of excellence in Pediatric Endocrinology including “Rina Balducci” Award of the Italian Society of Pediatric Endocrinology and Diabetology, “Georgio Kalaitzoglou Award of Excellence in Pediatric Endocrinology” from the Hellenic Society For Pediatric and Adolescent Endocrinology, Athens 2019 and “Premio Cacciari” Award of Excellence in Pediatric Endocrinology” from the Italian Society of Pediatric Endocrinology and Diabetology SIEDP/ISPED, Bologna 2023. Professor Maghnie’s major research interests include growth disorders and their treatment and the management of pediatric pituitary disorders. He has authored over 325 original articles, textbook chapters and scholarly reviews in a number of high impact journals, as well as numerous book chapters.

All Scientific Seminars International Foundation programmes are organized solely to promote the exchange and dissemination of scientific and medical information. No forms of promotional activities are permitted. There may be presentations discussing investigational uses of various products. These views are the responsibility of the named speakers, and do not represent an endorsement or recommendation on the part of Scientific Seminars International Foundation.

This independent educational programme is made possible thanks to an educational grant received from Merck Healthcare KGaA Darmstadt, Germany.

For registration
CLICK HERE

Scientific Seminars International Foundation
Via di Porta Pinciana, 6 - 00187 Roma
www.scientificseminars.com